Neuren Pharmaceuticals Ltd has released a press release.
First patient dosed in Neuren PMS Phase 3 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren receives US FDA meeting feeback for HIE and PTHS
- Trading Halt
- Acadia provides update on EU regulatory submission
- Response to ASX Aware Letter
- DAYBUE net sales projected to reach approx US$700m in 2028
Later from Neuren Pharmaceuticals
- Neuren to commence new on-market share buy-back program
- Pause in Trading
- Acadia reports DAYBUE net sales for 2025 and 2026 guidance
- Appendix 4E and 2025 full year accounts
- 2025 royalty income A$65m, profit after tax A$30m
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals